Mode
Text Size
Log in / Sign up

Euonymus alatus may improve glucose metabolism and reduce urinary protein in diabetic nephropathyPlant extract shows promise in managing diabetes and kidney health

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that Euonymus alatus shows potential for improving glucose and lipid metabolism, but clinical evidence is limited.

This systematic review synthesizes preclinical and clinical evidence regarding the effects of Euonymus alatus on diabetes, diabetic nephropathy, and retinopathy. The authors conclude that Euonymus alatus may offer therapeutic potential by reducing blood glucose in both preclinical models and clinical settings, as well as reducing urinary protein levels.

The synthesis suggests several biological pathways for these effects. Specifically, the review notes that Euonymus alatus may inhibit alpha-glucosidase activity, ameliorate insulin resistance via PPARG and PI3K/Akt pathways, and improve lipid metabolism through DGAT activity regulation. Additionally, it is reported to modulate gut microbiota composition, increase short-chain fatty acid production, and suppress oxidative stress and inflammatory responses via RAGE, NF-kB, and MAPK pathways.

Several limitations are noted by the authors, including limited clinical evidence and small sample sizes. The lack of rigorous controls and the multi-botanical nature of Euonymus alatus compositions make it difficult to attribute specific effects to individual components. Furthermore, pharmacokinetic parameters for any Euonymus alatus metabolite have not been experimentally determined. Clinical evidence remains limited, and these findings should be interpreted with caution in clinical practice.

How this fits prior evidence

This review addresses a gap in the management of diabetic complications by exploring botanical interventions like Euonymus alatus. While prior coverage has established that PCSK9 inhibitors provide consistent reductions in major adverse cardiovascular events for patients with diabetes mellitus, this finding explores an alternative botanical approach to managing glucose and renal markers. It does not directly relate to the risk factors for sarcopenia or the scoring systems for renal tumor ablation mentioned in previous reports.

Living with diabetes often means managing more than just blood sugar. It can also lead to serious complications like kidney damage or vision issues. Researchers are looking into how certain natural compounds might help manage these risks. A review of the plant Euonymus alatus suggests it may offer some protection against these complications.

In both laboratory tests and small clinical studies, this plant extract showed several positive signs. It helped lower blood glucose levels and reduced the amount of protein lost in urine, which is a key sign of kidney health. The research also found that the extract might improve how the body handles insulin and reduce inflammation and stress on cells.

While these results are encouraging, we must be careful with the conclusions. Most of the evidence comes from early laboratory tests or small groups of people. Because the plant is a complex mixture, it is hard to tell exactly which part of it is doing the work. More large-scale clinical trials are needed to see if it can truly help patients in everyday practice.

What this means for you:
Euonymus alatus shows potential for lowering blood sugar and protecting kidneys, but more human trials are needed.

Common questions

Can this plant help with my diabetes?

Early research shows that Euonymus alatus can lower both fasting blood glucose and general blood glucose. It also appears to improve insulin resistance by working through specific biological pathways. However, because clinical evidence is currently limited, you should talk to your doctor before making any changes to your treatment.

Does it help with kidney problems caused by diabetes?

The review found that the plant extract reduced urinary protein in clinical settings. High levels of protein in urine are a sign of kidney damage from diabetes. While this is a positive finding, the study notes that small sample sizes and limited evidence mean more research is needed.

Is it safe to use as a treatment?

The current review does not provide specific data on safety or side effects for humans. Because the plant is a complex mixture, it is hard to know exactly how it works. You should always consult a medical professional before using any herbal supplements.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Euonymus alatus: (EA), a traditional Chinese botanical drug documented in the Shennong Ben Cao Jing, has been investigated for its potential anti-diabetic effects. This review systematically examines the phytochemistry, pharmacokinetics, and anti-diabetic mechanisms of this botanical drug. Over 230 metabolites, including flavonoids, triterpenoids, and lignans, have been identified from EA. Pharmacokinetic studies remain limited; computational predictions suggest that some metabolites may exhibit oral bioavailability, but classical pharmacokinetic parameters have not been experimentally determined for any EA metabolite. Mechanistic studies demonstrate that EA exerts anti-diabetic effects through multiple experimentally validated pathways: (i) inhibiting alpha-glucosidase activity to delay intestinal glucose absorption; (ii) activating the peroxisome proliferator-activated receptor gamma and phosphatidylinositol 3-kinase/protein kinase B signaling pathways to ameliorate insulin resistance; (iii) modulating gut microbiota composition and increasing short-chain fatty acid production; (iv) suppressing the advanced glycation end products-receptor for advanced glycation end products axis along with the nuclear factor kappa B and mitogen-activated protein kinase inflammatory pathways to alleviate oxidative stress and inflammatory responses; and (v) regulating diacylglycerol acyltransferase activity to improve lipid metabolism. Preclinical studies indicate that EA reduces blood glucose and improves markers of diabetic nephropathy and retinopathy. Clinical studies of EA-containing formulations report reductions in fasting blood glucose and urinary protein. However, the clinical evidence remains limited by small sample sizes, lack of rigorous controls, and multi-botanical drug compositions that preclude attribution of effects to individual components. This review provides a critical synthesis of current evidence and identifies priorities for future investigation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.